Quantitative analysis for Relmada Therapeutics, Inc. (RLMD) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (59.0) (grade B). Gem alpha score: 46.0. 30 signals analyzed (26 differentiated alt-data).
RLMD stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-30 | $7.58 | $7.25 | $7.52 |
| 2026-05-12 | $7.48 | $7.09 | $7.45 |
| 2026-05-22 | $7.50 | $7.01 | $7.04 |
| 2026-06-04 | $6.44 | $6.24 | $6.31 |
| 2026-06-16 | $6.59 | $6.27 | $6.55 |
| 2026-06-29 | $7.05 | $6.49 | $6.98 |
| 2026-07-10 | $6.53 | $6.19 | $6.41 |
| 2026-07-22 | $5.25 | $4.95 | $5.00 |
| 2026-08-03 | $5.46 | $5.06 | $5.30 |
| 2026-08-13 | $4.89 | $4.66 | $4.75 |
| 2026-08-25 | $4.72 | $4.57 | $4.59 |
| 2026-09-04 | $4.44 | $4.32 | $4.43 |
How Relmada Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CBIO | Crescent Biopharma, Inc. | $521M | — |
| GMRS | GMR Solutions Inc. | $533M | 40.0 |
| PROK | ProKidney Corp. | $545M | — |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $501M | — |
View all Health Care stocks by valuation and signals →
Relmada Therapeutics, Inc. (RLMD) scores Buy (59.0), with no measured dimension below 51. Its highest are AI Alpha (gem) at 88, competitive moat at 84, valuation at 72, across 7 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| AI Alpha (gem) | 88 |
| competitive moat | 84 |
| valuation | 72 |
| ML forecast | 65 |
| analyst consensus | 58 |
| technicals | 58 |
| earnings quality | 51 |
StoQuant analyzes 30 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Relmada Therapeutics, Inc. (RLMD): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/RLMD"><img src="https://stoquant.com/badge/RLMD.svg" alt="Relmada Therapeutics, Inc. (RLMD) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.